多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
84.3分
★★★★☆
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
ALL SOURCES
全部资讯 15
条件筛选 · 已选 3 项 · 共 15 条展开收起
多发性骨髓瘤的新型免疫靶点：生物学意义与治疗潜力
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.
69.3分
★★★☆☆
站内排序·非疗效
靶向 BCMA 或 GPRC5D 的双特异性抗体在 CAR-T 细胞治疗后复发多发性骨髓瘤中高度有效
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
65.5分
★★★☆☆
站内排序·非疗效
ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
63.4分
★★★☆☆
站内排序·非疗效
整合免疫疗法治疗多发性骨髓瘤
Integrating Immune Therapies for the Treatment of Multiple Myeloma.
63.3分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤中 CAR-T 或 BiTE 治疗的患者选择：每位患者应选择哪种治疗？
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
62.5分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤中的单特异性和双特异性嵌合抗原受体（CAR）T 细胞治疗：系统综述、荟萃分析与荟萃回归
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression
56.0分
★★★☆☆
站内排序·非疗效
双特异性抗体在多发性骨髓瘤中的演进
The evolution of bispecific antibodies in multiple myeloma.
46.3分
★★★☆☆
站内排序·非疗效
无限可能以及如何利用它们？最佳治疗顺序是什么？
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
43.3分
★★☆☆☆
站内排序·非疗效
SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗：非 CAR-T 细胞
SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.
40.6分
★★☆☆☆
站内排序·非疗效